On the basis of the results from ARCHER 1050, dacomitinib was approved for the first-line treatment of patients with metastatic NSCLC containing EGFR exon 19 deletion or exon 21 L858R substitution in the United States and the European Union [2,6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.